Synchron, Nvidia showcase AI for brain-computer interfaces - NEWS - 20.03.25
pharmaphorum
Industry leading publications, strategic consulting and a content-driven stakeholder engagement agency
This Thursday, brain-computer interface specialist Synchron has previewed an AI model that it believes will form the basis of a new generation of devices.
Elsewhere, less than 18 months after its IPO, CAR-T developer CARGO has abandoned its development efforts and slashed around 90% of its staff, and Sanofi has signed a $1.9bn deal to buy Dren Bio’s autoimmune drug.
In other news, a study of Roche's anti-amyloid drug gantenerumab has suggested that early treatment to remove amyloid plaques from the brain years before symptoms arise may delay the onset of Alzheimer's dementia – although some specialists have urged caution in interpreting the data – and UK pharma leaders have renewed calls for a rethink by the government on levies imposed on medicine sales, saying investment is already being hit.
And in our longer reads, discover more about AI in cancer diagnostics and devices and find out the process behind patent strategies for dual-use innovations. There’s also a new podcast with editor-in-chief Jonah Comstock and Alice Valder Curran on the Inflation Reduction Act to tune into…
All this and more on pharmaphorum.com.
News
Brain-computer interface specialist Synchron has previewed an AI model that it believes will form the basis of a new generation of devices.
Less than 18 months after its IPO, CAR-T developer CARGO has abandoned its development efforts and slashed around 90% of its staff.
Sanofi buys a drug from Dren Bio to claim a stake in the emerging field of deep B-cell depletion for autoimmune diseases.
A study has suggested early targeting of amyloid in the brains of people with inherited Alzheimer's can delay symptoms, but not all are convinced.
UK pharma leaders have renewed calls for a rethink by the government on levies imposed on medicine sales, saying investment is already being hit.
Views & Analysis
While it’s only relatively recently that AI became a household term, the technology is already having a major impact on society. But perhaps AI’s greatest impact has been in the medical field, specifically in the areas of diagnostics and devices.
In the pharmaceutical and cosmetic sectors, innovation often stems from discovering new applications for known compounds. In these situations, an innovator cannot patent the compound itself – since the compound itself is not novel.
Recent progress in oncological pharmacotherapy has resulted in more complex treatment options and adverse event management, widening gaps in care quality between specialised centres and local hospitals.
In clinical research, there is no such thing as ‘taking a leap of faith’ and yet the industry’s need for empirical certainty can sometimes thwart adoption of important innovation.
Small biotech companies encounter significant challenges in designing and implementing clinical development programmes. These companies have an even lower rate of success than that of large, established companies, due to limited internal experience in clinical development and limited infrastructure.
Podcasts & Videos
On a new podcast with Jonah Comstock, Curran joins us once again for an update on the IRA, looking at the second batch of drugs announced in January, recent messaging from the Centers for Medicare and Medicaid Services and what it might communicate about their thinking, and more analysis of IRA’s consequences, including a recent study on the impact of the IRA on early stage investment.
More than 150 million doses of the seasonal flu vaccine are administered each year in the US alone. But in recent years that shot has only been 30 to 40% effective. While this is certainly better than nothing from a public health perspective, a number of companies see an opportunity to create a more effective flu vaccine and, ideally, one that doesn’t have to be re-formulated and redeveloped every year.
One of the key open questions in cell and gene therapy is which will win out: autologous cell therapies or allogeneic therapies? At JP Morgan 2025, editor-in-chief Jonah Comstock spoke with the co-CEOs of Medipost, Tony Lee and Ed Ahn, about creating an allogeneic cell therapy product in Korea for the treatment of osteoarthritis – the first allogeneic cell therapy to secure regulatory approval anywhere in the world.
领英推荐
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Bryan Hill, life sciences chief technology officer at Cognizant, in a conversation on how generative AI is revolutionising life sciences and drug development.
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Jason Bock, co-founder and CEO of CTMC, a first-of-its-kind cell therapy engine.
Webinars & White Papers
In this webinar, sponsored by IPG Health, discover how industry insiders are unlocking the potential of CGTs in rare disease care, the unique hurdles facing pharma and patients, and the transformative opportunities these therapies bring.
In a new white paper from Altmetric – ‘The changing landscape of journal performance measurement’ – learn how publication planners and medical affairs communications teams can leverage the new impact metrics that matter for journal selection.
In a recent webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possible’, this forward-looking session explored how imagination and innovation are reshaping the future of healthcare. Available now on demand.
In a new white paper from the World Without Disease initiative, a 2024 update is provided of the endeavours and developments that occurred since inaugural discussions 2023.
A panel of experts, including from IPG Health, have shared their sector experience and wisdom in a new 60 Seconds white paper, ‘Moments of Truth: Launch’, to highlight the need to create and champion an organisational culture that underwrites a new product’s potential.
Meet With Us! Upcoming Events
26th-28th March
3rd April
9th-11th April
Partner Content and Events
The 2nd Peptide Formulation & Delivery Innovation Summit returns on June 24 - 26, 2025 in Boston, MA.
The 4th LNP Formulation & Process Development Summit is the largest forum dedicated to the end-to-end LNP Development.
Transforming Cell- & Biologic-based TCR Approaches
Diversifying ADC Payloads as Warheads for Overcoming Tumor Resistance, With Optimized Efficacy, Potency, Mechanisms & Differentiated IP
The 3rd Obesity & Weight Loss Drug Development Summit is the place to be for experts in weight loss drug development tackling the obesity epidemic.